Premium
What Patients and Their Relatives Think About Testing for BMPR2
Author(s) -
Jones Diana L.,
Sandberg Joanne C.,
Rosenthal Mary J.,
Saunders Robert C.,
Hannig Vickie L.,
Clayton Ellen W.
Publication year - 2008
Publication title -
journal of genetic counseling
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 52
eISSN - 1573-3599
pISSN - 1059-7700
DOI - 10.1007/s10897-008-9172-1
Subject(s) - genetic testing , genetic counseling , medicine , predictive testing , telephone interview , bmpr2 , family medicine , genetics , social science , sociology , gene , biology , bone morphogenetic protein
Clinical genetic testing is available for mutations in BMPR2 associated with pulmonary arterial hypertension (PAH). The aim of this study is to assess attitudes of individuals affected by or at risk for PAH regarding genetic testing. Structured telephone interviews were conducted with 119 individuals affected by or at risk for PAH recruited from pulmonary hypertension clinic at Vanderbilt, Vanderbilt familial PAH registry, attendees at 2006 PHA meeting, and a local PAH support group. Sixty‐four percent reported knowing little or nothing about BMPR2 testing. Predictors of greater self‐assessed knowledge included having an affected family member and learning about BMPR2 testing through the internet. Most respondents reported that while they spent some time thinking about being tested for BMPR2, they had little trouble deciding. The most frequently cited reason for testing was to provide information for their children. About 20% said they had been tested, even though <5% have actually received clinical testing. Although patients with PAH and their at‐risk relatives typically feel relatively uninformed about testing for mutations in BMPR2 and at times are confused about their testing status, they nonetheless report that it is easy to decide about testing.